Bank of New York Mellon Corp Purchases 11,877 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Bank of New York Mellon Corp raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 397,378 shares of the specialty pharmaceutical company’s stock after purchasing an additional 11,877 shares during the quarter. Bank of New York Mellon Corp owned 0.71% of Supernus Pharmaceuticals worth $12,525,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Yousif Capital Management LLC grew its holdings in shares of Supernus Pharmaceuticals by 1.5% during the second quarter. Yousif Capital Management LLC now owns 21,032 shares of the specialty pharmaceutical company’s stock valued at $663,000 after buying an additional 305 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Supernus Pharmaceuticals by 2.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company’s stock valued at $480,000 after acquiring an additional 350 shares in the last quarter. Maryland State Retirement & Pension System boosted its stake in Supernus Pharmaceuticals by 2.2% during the 2nd quarter. Maryland State Retirement & Pension System now owns 16,455 shares of the specialty pharmaceutical company’s stock valued at $519,000 after purchasing an additional 361 shares during the last quarter. Bank of Montreal Can increased its holdings in Supernus Pharmaceuticals by 4.9% during the 2nd quarter. Bank of Montreal Can now owns 10,144 shares of the specialty pharmaceutical company’s stock worth $320,000 after purchasing an additional 475 shares in the last quarter. Finally, Vident Advisory LLC raised its stake in shares of Supernus Pharmaceuticals by 3.4% in the first quarter. Vident Advisory LLC now owns 14,886 shares of the specialty pharmaceutical company’s stock worth $488,000 after purchasing an additional 494 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $44.90 on Wednesday. The company has a market capitalization of $2.57 billion, a P/E ratio of 39.04 and a beta of 0.75. The company’s 50-day moving average is $48.55 and its 200 day moving average is $40.22. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The company had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a return on equity of 14.22% and a net margin of 9.70%.The business’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the business posted $0.69 EPS. Supernus Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several recent research reports. Cantor Fitzgerald upped their price target on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a report on Tuesday, September 30th. Weiss Ratings downgraded shares of Supernus Pharmaceuticals from a “hold (c+)” rating to a “sell (d+)” rating in a report on Thursday, November 13th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 17th. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $40.00 to $65.00 in a report on Thursday, October 9th. Finally, TD Cowen upped their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $63.25.

Insider Buying and Selling

In other news, CFO Timothy C. Dec sold 11,780 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the transaction, the chief financial officer owned 1,246 shares of the company’s stock, valued at $55,434.54. This represents a 90.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Frank Mottola sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $45.87, for a total value of $229,350.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares of the company’s stock, valued at approximately $710,801.52. This trade represents a 24.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 209,915 shares of company stock valued at $9,965,819. 8.80% of the stock is owned by company insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.